ID 4454 - Kwas gamma-linolenowy

PL: Kwas gamma-linolenowy
EN: Gamma linolenic acid (GLA)
Pdf:

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituents that are the subject of the health claims are "gamma-linolenic acid (GLA; C18: 3n-6) provided by evening primrose oil and/or borage (starflower) oil", "gamma-linolenic acid", "evening primrose oil (Oenothera biennis) contains gamma-linolenic acid", "borage oil (GLA= gamma linolenic acid)", "oenothera biennis-evening primrose-seeds oil", "long chain omega 6 polyunsaturated fatty acid GLA (gamma-linolenic acid)", "Borago officinalis", and "GLA (example from Borago officinalis, primrose oil, black currant seed oil)".
In the context of the proposed health relationships, wordings, conditions of use, and the clarifications provided by Member States, the Panel assumes that the food constituent that is the subject of the health claims is gamma-linolenic acid (GLA).
GLA is a n-6 long-chain polyunsaturated fatty acid which is present in small amounts in a variety of foods of both plant and animal origin and which can also be synthesised in the human body from its precursor linoleic acid (LA). GLA is a well recognised nutrient and can be measured in foods by established methods. This evaluation applies to GLA from all sources.
The Panel considers that the food constituent, gamma-linolenic acid (GLA), which is the subject of the health claims, is sufficiently characterised.

2.8. Właściwości przeciwzapalne (ID 4454)

The claimed effect is "anti-inflammatory due to gamma-linolenic acid (GLA)".
Inflammation is a non-specific physiological response to tissue damage that is mediated by the immune system. Adequate inflammatory responses are of primary importance for the defence against injury of any origin. In the context of the proposed wordings, the Panel assumes that the target population is patients with clinical conditions (e.g. atopic eczema, mastalgia), in which a reduction of inflammation could represent a therapeutic target for the treatment of the condition.
The Panel considers that the reduction of inflammation in the context of chronic clinical conditions is a therapeutic target for the treatment of the condition and does not comply with the criteria laid down in Regulation (EC) No 1924/2006.

Warunki i możliwe ograniczenia stosowania oświadczenia